KR102253394B1 - 골관절염의 예방 및 치료를 위한 스테로이드류 및 졸레드론산의 공투여 - Google Patents

골관절염의 예방 및 치료를 위한 스테로이드류 및 졸레드론산의 공투여 Download PDF

Info

Publication number
KR102253394B1
KR102253394B1 KR1020157027348A KR20157027348A KR102253394B1 KR 102253394 B1 KR102253394 B1 KR 102253394B1 KR 1020157027348 A KR1020157027348 A KR 1020157027348A KR 20157027348 A KR20157027348 A KR 20157027348A KR 102253394 B1 KR102253394 B1 KR 102253394B1
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
prednisolone
acceptable salt
zoledronic acid
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157027348A
Other languages
English (en)
Korean (ko)
Other versions
KR20150125001A (ko
Inventor
케탄 데사이
Original Assignee
레볼타 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레볼타 파마슈티칼스, 인크. filed Critical 레볼타 파마슈티칼스, 인크.
Publication of KR20150125001A publication Critical patent/KR20150125001A/ko
Application granted granted Critical
Publication of KR102253394B1 publication Critical patent/KR102253394B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
KR1020157027348A 2013-03-08 2014-03-07 골관절염의 예방 및 치료를 위한 스테로이드류 및 졸레드론산의 공투여 Expired - Fee Related KR102253394B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/791,685 US9012432B2 (en) 2013-03-08 2013-03-08 Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
US13/791,685 2013-03-08
PCT/US2014/022169 WO2014138712A1 (en) 2013-03-08 2014-03-07 Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis

Publications (2)

Publication Number Publication Date
KR20150125001A KR20150125001A (ko) 2015-11-06
KR102253394B1 true KR102253394B1 (ko) 2021-05-20

Family

ID=51488530

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157027348A Expired - Fee Related KR102253394B1 (ko) 2013-03-08 2014-03-07 골관절염의 예방 및 치료를 위한 스테로이드류 및 졸레드론산의 공투여

Country Status (12)

Country Link
US (1) US9012432B2 (cg-RX-API-DMAC10.html)
EP (1) EP2964209B1 (cg-RX-API-DMAC10.html)
JP (2) JP6839491B2 (cg-RX-API-DMAC10.html)
KR (1) KR102253394B1 (cg-RX-API-DMAC10.html)
CN (1) CN105324113B (cg-RX-API-DMAC10.html)
AU (1) AU2014225373B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015021503B1 (cg-RX-API-DMAC10.html)
CA (1) CA2941346C (cg-RX-API-DMAC10.html)
EA (1) EA032067B1 (cg-RX-API-DMAC10.html)
ES (1) ES2904365T3 (cg-RX-API-DMAC10.html)
MX (1) MX377447B (cg-RX-API-DMAC10.html)
WO (1) WO2014138712A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3428178A4 (en) 2016-03-09 2019-09-04 Bio Pep Co., Ltd. PEPTIDE FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES AND USE THEREOF
WO2017155234A1 (ko) 2016-03-09 2017-09-14 주식회사 바이오펩 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도
KR101897122B1 (ko) 2016-03-09 2018-09-10 주식회사 바이오펩 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도
US10913772B2 (en) 2016-03-09 2021-02-09 Kine Sciences Co., Ltd. Peptide for preventing or treating inflammatory diseases and use thereof
US10913771B2 (en) 2016-03-09 2021-02-09 Kine Sciences Co., Ltd. Peptide for preventing or treating inflammatory diseases and use thereof
JP7127616B2 (ja) 2019-06-04 2022-08-30 横河電機株式会社 情報処理装置、アラーム管理システム、及びアラーム管理方法
WO2021163432A1 (en) * 2020-02-12 2021-08-19 Levolta Pharmaceuticals, Inc. Co-administration of prednisolone/methyl prednisolone and zoledronic acid to treat and prevent osteoarthritis
CN114028571B (zh) * 2021-11-18 2023-04-28 中国医学科学院基础医学研究所 含氮双膦酸盐联合糖皮质激素在预防或治疗病毒性肺炎中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110263537A1 (en) * 2010-04-26 2011-10-27 Ketan Desai Co-administration of steroids and zoledronic acid to prevent and treat side effects from zoledronic acid infusion

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2038692T4 (es) 1986-11-21 2012-02-10 Novartis Ag Procedimiento para la obtencion de acidos alcanodifosfonicos substituidos.
WO2001047559A1 (fr) * 1999-12-27 2001-07-05 Teikoku Seiyaku Co., Ltd Pastilles a usage externe
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
EP1402066A4 (en) * 2001-06-08 2008-10-22 Ortho Mcneil Pharm Inc PAIN TREATMENT WITH HYPERPOLARIZATION ACTIVATED CHANNELS CONTROLLED BY CYCLIC NUCLEOTIDE AS ATTACK POINT
WO2003086415A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
AU2004273672A1 (en) * 2003-09-19 2005-03-31 Wisconsin Alumni Research Foundation Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphonate
JP2008502609A (ja) * 2004-06-17 2008-01-31 オステオロジックス エイ／エス リウマチおよび関節性疾患の治療改善方法
ES2396976T3 (es) * 2005-05-25 2013-03-01 Calosyn Pharma, Inc Método y composición para tratar osteoartritis
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
PT2049123E (pt) * 2006-08-03 2013-03-06 Horizon Pharma Ag Tratamento de doença reumatóide com glucocorticóide de libertação retardada
US20100158905A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy of arthritis with tranilast
EP2427160A4 (en) * 2009-05-04 2012-12-19 Zars Pharma Inc METHOD FOR TREATING PAIN RELATED TO NEUROMAS, NERVE CLAIMS AND OTHER SUFFERING PAINS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110263537A1 (en) * 2010-04-26 2011-10-27 Ketan Desai Co-administration of steroids and zoledronic acid to prevent and treat side effects from zoledronic acid infusion

Also Published As

Publication number Publication date
JP6839491B2 (ja) 2021-03-17
MX377447B (es) 2025-03-10
EP2964209A1 (en) 2016-01-13
EA032067B1 (ru) 2019-04-30
CA2941346A1 (en) 2014-09-12
BR112015021503B1 (pt) 2022-09-06
EA201591638A1 (ru) 2016-02-29
ES2904365T3 (es) 2022-04-04
EP2964209B1 (en) 2021-10-27
US9012432B2 (en) 2015-04-21
KR20150125001A (ko) 2015-11-06
MX2015011671A (es) 2016-05-12
CN105324113B (zh) 2018-07-03
EP2964209A4 (en) 2016-08-03
AU2014225373A1 (en) 2015-10-22
AU2014225373B2 (en) 2018-07-05
CA2941346C (en) 2020-03-10
CN105324113A (zh) 2016-02-10
JP2019104762A (ja) 2019-06-27
BR112015021503A2 (en) 2018-05-15
JP2016510765A (ja) 2016-04-11
US20140256681A1 (en) 2014-09-11
WO2014138712A1 (en) 2014-09-12

Similar Documents

Publication Publication Date Title
US8859530B2 (en) Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
AU2014225373B2 (en) Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
US20250295869A1 (en) Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
US8946199B2 (en) Co-administration of steroids and Zoledronic acid to prevent and treat side effects from Zoledronic acid infusion
US20140194388A1 (en) Combination therapy of hsp90 inhibitory compounds with chk inhibitors
JP2018087228A (ja) がんのためのグルフォスファミド組み合わせ療法
Scott et al. Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma
CN110494137B (zh) 哺乳类雷帕霉素靶蛋白抑制剂及氯喹于治疗癌症的用途
US20060217425A1 (en) Methods of treating cancer using PPAR-gamma antagonists
WO2021163432A1 (en) Co-administration of prednisolone/methyl prednisolone and zoledronic acid to treat and prevent osteoarthritis
IT202100009926A1 (it) Una combinazione comprendente un inibitore di hdac6 specifico e almeno un inibitore del checkpoint ctla4
US20250177352A1 (en) Combination treatment for cancer
CN105283185A (zh) 用于治疗何杰金氏淋巴瘤的4-氰基-n-(2-(4，4-二甲基环己-1-烯-1-基)-6-(2，2，6，6-四甲基四氢-2h-吡喃-4-基)吡啶-3-基)-1h-咪唑-2-酰胺
AU2011279391A1 (en) Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

D12-X000 Request for substantive examination rejected

St.27 status event code: A-1-2-D10-D12-exm-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250513

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250513

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250513